Aoki A, Suda A, Nagaoka S, Takeno M, Ishigatsubo Y, Ashizawa T, Ohde S, Takahashi O, Ohbu S: Preferences of Japanese rheumatoid arthritis patients in treatment decision-making. Mod Rheumatol, PMID:23053717, 2012.
Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori SI, Sakamaki H, Yabe H, Miyamoto T, Kanamori H, Ueda Y, Kawa K, Kato K, Suzuki R, Atsuta Y, Tamaki T, Kanda Y: Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: A retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood and Marrow Transplant, 18 (9): 1407-1414, 2012.
Hama M, Takase K, Ihata A, Ohno S, Ueda A, Takeno M, Ishigatsubo Y: Challenges to expanding the clinical application of musculoskeletal ultrasonography (MSUS) among rheumatologists: from a second survey in Japan. Mod Rheumatol, 22(2): 202-208, 2012.
Hama M, Kirino Y, Takeno M, Takase K, Miyazaki T, Yoshimi R, Ueda A, Itoh-Nakadai A, Muto A, Igarashi K, Ishigatsubo Y: Bach1 regulates osteoclastogenesis in a mouse model via both heme oxygenase 1-dependent and heme oxygenase 1-independent pathways. Arthritis Rheum, 64(5): 1518-1528, 2012.
Harigai M, Tanaka Y, Maisawa S; JA21963 Study Group: Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol, 39(3):486-95,2012.
Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y: Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis, Mod Rheumatol, 22(3):405-13, 2012.
Ishii Y, Tomita N, Takasaki H, Ogusa E, Hattori Y, Matsuura S, Matsumoto C, Takemura S, Kuwabara H, Ishigatsubo Y: Clinical features of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Hematol Oncol, 30(4): 186-189, 2012.
Ishii Y, Tomita N, Sakata S, Takeuchi K, Tateishi U, Watanabe R, Sakai R, Ishigatsubo Y: Maximum standard uptake value at the biopsy site during (18)F-fluorodeoxyglucose positron emission tomography does not predict the proliferation potential of tumor cells in extranodal natural killer/t cell lymphoma, nasal type. Acta Haematol, 128(2): 110-112, 2012.
Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R: Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res, 18(15): 4183-4190, 2012.
Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, Kurokawa M, Kanamori H, Mori T, Hidaka M, Iwato K, Yoshida T, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Kanda Y: Related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction and HLA 8/8-allele-matched unrelated transplantation: a nationwide retrospective study. Blood,119(10): 2409-2416, 2012.
Kato H, Ueda A, Tsukiji J, Sano K, Yamada M, Ishigatsubo Y. Salmonella enterica serovar Ohio septic arthritis and bone abscess in an immunocompetent patient: a case report. J Med Case Rep. 6(1): 204, 2012.
Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, Ustek D, Satorius C, Ueda A, Takeno M, Kim Y, Wood GM, Ombrello MJ, Meguro A, Gul A, Remmers EF, Kastner DL: Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B* 51 and ERAP1. Nat Genet, 45(2): 202-207, 2012.
Miyazaki T, Fujita H, Fujimaki K, Hosoyama T, Watanabe R, Tachibana T, Fujita A, Matsumoto K,
Tanaka M, Koharazawa H, Taguchi J, Tomita N, Sakai R, Fujisawa S, Kanamori H, Ishigatsubo Y: Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res, 236(8): 998-1003, 2012.
Mizuta S, Matsuo K, Maeda T, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Takada S, Yokota A, Takatsuka Y, Tamaki S, Imai K, Moriuchi Y, Miyazaki Y, Ohtake S, Ohnishi K, Naoe T: Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J, 2(5): e72, 2012.
Numata A, Tomita N, Fujimaki K, Tanaka M, Hashimoto C, Oshima R, Matsumoto K, Matsuura S, Yamamoto W, Motomura S, Ishigatsubo Y: Retrospective study of the ulitility of FLIPI/FLIPI-2 for Follicular Lymphoma patients treated with R-CHOP. J Clin Exp Hematop, 52(1): 77-79, 2012.
Numata A, Tanaka M, Tachibana T, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori K: Successful treatment with deferasirox in a patient with secondary hemochromatosis following allogeneic stem cell transplantation for acute lymphoblastic leukemia. Journal of Hematopoietic Cell Transplantation, 1(1): 33-36, 2012.
Ogusa E, Tomita N, Ishii Y, Takasaki H, Hattori Y, Matsumoto C, Ishigatsubo Y: Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population, Hematol Oncol, 2012.
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N,
Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T: Long-term outcome of imatinib therapy, with assessment of its dosage and blood levels,for chronic myelogenous leukemia. Cancer Sci, 103(6): 1071-1078, 2012.
Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M: for the REAL Study Group. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis, 71(11): 1820-1826, 2012.
Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M: for the REAL Study Group. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken),64(8): 1125-1134, 2012.
Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, Kanda Y, Nakaseko C, Yano S, Fujita H, Fujisawa S, Miyawaki S, Kanamori H, Okamoto S: Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia, 26(12): 2469-2473, 2012.
Tachibana T, Tanaka M, Numata A, Takasaki H, Ito S, Ohshima R, Hagihara M, Yamazaki E, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H: Pretransplant serum ferritin has a prognostic influence on allogeneic transplantation regardless of disease risk. Leuk lymphoma, 53(3): 456-461, 2012.
Tachibana T, Tanaka M, Yamazaki E, Numata A, Takasaki H, Kuwabara H, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H: Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma, 2012.
Tachibana T, Tanaka M, Ishigatsubo Y, Kanamori H: Thrombosis at ascending aorta following chemotherapy in a patient with acute myeloid leukemia. Int J Hematol, 96(3): 293-294, 2012.
Takahashi H, Sakai R, Hattori Y, Ohshima R, Kuwabara H, Hagihara M, Enaka M, Nozawa A, Tomita N, Ishigatsubo Y, Fujisawa S: Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. Leuk Lymphoma. 2012.
Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, and Ishigatsubo Y: Prognostic Impact of Extranodal Involvement in Diffuse Large B-Cell Lymphoma in the Rituximab Era. Cancer, 118(17): 4166-4172, 2012.
Takasaki H, Tanaka M, Tachibana T, Numata A, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H,
Maruta A, Ishigatsubo Y, Kanamori H: Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy. Int J Hematol, 95(3): 291-298, 2012.
Takase K, Ohno S, Takeno M, Hama M, Kirino Y, Ihata A, Ideguchi H, Mochida Y, Tateishi U, Shizukuishi K, Nagashima Y, Aoki I, Ishigatsubo Y: Simultaneous evaluation of long-lasting knee synovitis in patients undergoing arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology. Clin Exp Rheumatol, 30(1): 85-92, 2012.
Takemura S, Tomita N, Koharazawa H, Fujimaki K, Harano H, Hyo R, Yamazaki E, Hashimoto C, Miyazaki T, Ishigatsubo Y: Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma. Int J Hematol, 96(2): 241-246, 2012.
Takeuchi M, Nakaseko C, Ohwada C, Sato Y, Ohashi K, Kakihana K, Mori T, Aisa Y, Kanda Y, Takahashi S, Yokota A, Kawaguchi T, Saitoh T, Hatsumi N, Taguchi J, Takasaki H, Kanamori H, Maruta A, Sakamaki H, Okamoto S: Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis: a retrospective, multicenter study of the Kanto Study Group for Cell Therapy (KSGCT). Journal of Hematopoietic Cell Transplantation, 1(1): 15-23, 2012.
Tanaka M, Tachibana T, Numata A, Takasaki H, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H: A prognositic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT. Bone Marrow Transplant, 47(4): 596-597, 2012.
Tanaka M, Kobayashi S, Numata A, Tachibana T, Takasaki H, Maruta A, Ishigatsubo Y, Kanamori H: The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leuk Res, 36(6): 699-703, 2012.
Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K: Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci, 103(3): 245-251, 2012.
Tomita N, Sakai R, Fujisawa S, Fujimaki K, Taguchi J, Hashimoto C, Ogawa K, Yamazaki E, Ishigatsubo Y: SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci, 103(8): 1518-1523, 2012.
Yamamoto W, Nakamura N, Tomita N, Ishii Y, Takasaki H, Hashimoto C, Motomura S, Yamazaki E, Ohshima R, Numata A, Ishigatsubo Y, Sakai R: Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum,Leuk Lymphoma,2012.
Yokota A, Ozawa S, Masanori T, Akiyama H, Ohshima K, Kanda Y, Takahashi S, Mori T, Nakaseko C, Onoda M, Kishi K, Doki N, Aotsuka N, Kanamori H, Maruta A, Sakamaki H, Okamoto S: Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant, 47(1): 95-100, 2012.
Yoshimi R, Hama M, Takase K, Ihata A, Kishimoto D, Terauchi K, Watanabe R, Uehara T, Samukawa S, Ueda A, Takeno M, Ishigatsubo Y: Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis. Mod Rheumatol. 2012.
Yoshimi R, Ishigatsubo Y, Ozato K: Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. Int J Rheumatol,718237,2012.
Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y: Clinical and pathological roles of Ro/SSA antibody system. Clin Dev Immunal,606195, 2012.
